Princess Alexandara Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Andelkovic, Vladimir
CHONQUER, NCT06127407: Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Recruiting
3
136
Europe, Canada, Japan, US, RoW
Ivosidenib 500mg, Placebo
Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
02/28
11/30
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
198
Europe, US, RoW
AL102, varegacestat, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT05910827: Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers

Recruiting
1/2
98
RoW
HMBD-001, Docetaxel, Cetuximab
Hummingbird Bioscience, Merck KGaA, Darmstadt, Germany
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma
03/26
03/26
MTX-GPC3-303, NCT06478693: A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Recruiting
1
48
RoW
MT-303
Myeloid Therapeutics
Hepatocellular Carcinoma
07/25
05/26
NCT05919537: Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Active, not recruiting
1
68
RoW
HMBD-001, Docetaxel, Nab-paclitaxel, Gemcitabine
Hummingbird Bioscience
Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
03/31
03/31
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Andelkovic, Vladimir
CHONQUER, NCT06127407: Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Recruiting
3
136
Europe, Canada, Japan, US, RoW
Ivosidenib 500mg, Placebo
Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
02/28
11/30
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
198
Europe, US, RoW
AL102, varegacestat, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT05910827: Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers

Recruiting
1/2
98
RoW
HMBD-001, Docetaxel, Cetuximab
Hummingbird Bioscience, Merck KGaA, Darmstadt, Germany
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma
03/26
03/26
MTX-GPC3-303, NCT06478693: A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Recruiting
1
48
RoW
MT-303
Myeloid Therapeutics
Hepatocellular Carcinoma
07/25
05/26
NCT05919537: Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Active, not recruiting
1
68
RoW
HMBD-001, Docetaxel, Nab-paclitaxel, Gemcitabine
Hummingbird Bioscience
Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
03/31
03/31

Download Options